Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans

Ken-ichi Umehara, Megumi Iwai, Yasuhisa Adachi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition June 2008, 36 (6) 1030-1038; DOI: https://doi.org/10.1124/dmd.108.020669
Ken-ichi Umehara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megumi Iwai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhisa Adachi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Iwatsubo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Usui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hidetaka Kamimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 36 no. 6 1030-1038
DOI 
https://doi.org/10.1124/dmd.108.020669
PubMed 
18332079

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received January 29, 2008
  • Accepted March 5, 2008
  • Published online May 19, 2008.

Article Versions

  • Earlier version (March 10, 2008 - 08:00).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ken-ichi Umehara,
  2. Megumi Iwai,
  3. Yasuhisa Adachi,
  4. Takafumi Iwatsubo,
  5. Takashi Usui and
  6. Hidetaka Kamimura
  1. Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan (K.U., M.I., T.I., T.U., H.K.); and ADME/TOX Research Institute, Sekisui Medical Co., Ltd., Ibaraki, Japan (Y.A.)
  1. Address correspondence to:
    Ken-ichi Umehara, Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. E-mail: kenichi.umehara{at}jp.astellas.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to May 2023

AbstractFullPdf
Aug 20171511
Sep 2017016610
Oct 201711176
Nov 20170139
Dec 20170132
Jan 20180206
Feb 20181166
Mar 2018093
Apr 20180176
May 20180133
Jun 20180114
Jul 20180116
Aug 20182155
Sep 2018243
Oct 2018164
Nov 2018072
Dec 2018621
Jan 2019300
Feb 2019621
Mar 2019711
Apr 2019735
May 20191112
Jun 2019504
Jul 20191201
Aug 20191111
Oct 20191300
Nov 20191621
Dec 20192402
Jan 20201100
Feb 2020600
Mar 2020600
May 2020211
Jun 20201612
Jul 20201000
Aug 2020600
Sep 2020901
Oct 20202024
Nov 2020601
Dec 20201000
Jan 20213232
Feb 20212841
Mar 20211840
Apr 20212021
May 20212421
Jun 20212860
Jul 20211913
Aug 20216161
Sep 2021520
Oct 20211641
Nov 20211513
Dec 20211710
Jan 2022711
Feb 20221011
Mar 2022511
Apr 20221841
May 2022610
Jun 20222111
Jul 20221618
Aug 20221311
Sep 20221310
Oct 20221320
Nov 20221626
Dec 20221813
Jan 20231341
Feb 20231222
Mar 2023710
Apr 2023616
May 20231934

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (6)
Drug Metabolism and Disposition
Vol. 36, Issue 6
1 Jun 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans

Ken-ichi Umehara, Megumi Iwai, Yasuhisa Adachi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition June 1, 2008, 36 (6) 1030-1038; DOI: https://doi.org/10.1124/dmd.108.020669

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans

Ken-ichi Umehara, Megumi Iwai, Yasuhisa Adachi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition June 1, 2008, 36 (6) 1030-1038; DOI: https://doi.org/10.1124/dmd.108.020669
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sex- and lifestyle-related factors affect hepatic CYP levels
  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics